Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study.

Trial Profile

Trastuzumab in a Neo-Adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TRAIN
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Results reporting the efficacy and toxicity of weekly paclitaxel-trastuzumab-carboplatin as neo-adjuvant treatment, published in the European Journal of Cancer.
    • 10 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top